Edition:
United States

NovaBay Pharmaceuticals Inc (NBY.A)

NBY.A on American Stock Exchange

4.00USD
5 Dec 2016
Change (% chg)

$0.10 (+2.56%)
Prev Close
$3.90
Open
$3.95
Day's High
$4.00
Day's Low
$3.90
Volume
4,593
Avg. Vol
10,463
52-wk High
$5.05
52-wk Low
$1.62

NBY.A

Chart for NBY.A

About

NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a... (more)

Overall

Beta: -0.19
Market Cap(Mil.): $61.30
Shares Outstanding(Mil.): 15.13
Dividend: --
Yield (%): --

Financials

  NBY.A Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -3.21 -- --
ROI: -226.83 -1.09 14.95
ROE: -452.33 -2.39 16.29

BRIEF-Novabay Pharmaceuticals Q3 sales $3.4 mln

* Novabay Pharmaceuticals says affirms outlook to reach positive adjusted cash flow from operations in December 2016

Nov 10 2016

BRIEF-Novabay Pharmaceuticals' Auriclosene demonstrates significant results in Phase 2B

* Novabay Pharmaceuticals' Auriclosene demonstrates statistically significant and clinically meaningful results in Phase 2B study for the prevention of urinary catheter blockage and encrustation

Sep 19 2016

BRIEF-NovaBay Pharmaceuticals posts Q2 loss per share $0.36

* NovaBay Pharmaceuticals reports 2016 second quarter financial results

Aug 11 2016

BRIEF-Pioneer Pharma (Singapore) Pte buys 1.3 mln shares of Novabay Pharmaceuticals

* Pioneer Pharma (Singapore) Pte. Ltd. reports acquisition of 1.3 mln shares of Novabay Pharmaceuticals Inc's Common Stock at $1.91 Per Share - SEC filing

Aug 02 2016

BRIEF-Novabay Pharmaceuticals completes $11.8 mln private placement

* Completes $11.8 million private placement Source text for Eikon: Further company coverage:

Aug 02 2016

BRIEF-Novabay Pharmaceuticals appoints Mark Sieczkarek president and CEO

* On track to achieve target of positive cash flow from operations by end of 2016 & accelerated revenue growth beyond

Jun 13 2016

BRIEF-Novabay Pharmaceuticals files for offering of 581,423 shares of common stock issuable upon exercise of outstanding warrants

* Files for offering of 581,423 shares of co's common stock issuable upon exercise of outstanding warrants Source text (http://1.usa.gov/1UpZZOQ) Further company coverage:

Jun 09 2016

Competitors

  Price Chg
PuriCore plc (PURI.L) 29.75p 0.00
C R Bard Inc (BCR.N) $210.21 +0.25
Smith & Nephew plc (SN.L) 1,106.00p -1.00
Abbott Laboratories (ABT.N) $38.43 +0.53
GlaxoSmithKline plc (GSK.L) 1,451.00p -8.00
3M Co (MMM.N) $171.62 -0.81
Sanofi SA (SASY.PA) €74.44 -1.62
Pfizer Inc. (PFE.N) $31.59 -0.04
Novartis AG (NOVN.S) CHF69.55 +0.05
Johnson & Johnson (JNJ.N) $111.94 -0.02

Earnings vs. Estimates